A study of referral bias in NMOSD and MOGAD cohorts

被引:1
|
作者
Rato, Miguel Leal [1 ,2 ]
Chen, Bo [2 ,3 ]
Francis, Anna [2 ]
Messina, Silvia [2 ]
Miron, Madalina [2 ]
Sharawakanda, Yvonne [2 ]
O'Sullivan, Eoin [4 ]
Cooper, Sarah [5 ]
Fisniku, Leonora [6 ]
Halfpenny, Christopher [7 ]
Martin, Roswell [8 ]
Hobart, Jeremy [9 ]
Rashid, Waqar [10 ]
Hemingway, Cheryl [11 ]
Williams, Victoria [12 ]
Hacohen, Yael [13 ]
Dobson, Ruth [14 ]
Ramdas, Sithara [15 ]
Leite, Maria Isabel [2 ]
Palace, Jacqueline [2 ]
Geraldes, Ruth [2 ]
机构
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Neurociencias & Saude Mental, Serv Neurol, Lisbon, Portugal
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Level 3,West Wing,Headley Way, Oxford OX3 9DU, England
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China
[4] Kings Coll Hosp London, Eye Dept, London, England
[5] Univ Hosp Sussex, Worthing, Sussex, England
[6] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
[7] Univ Hosp Southampton, Southampton, England
[8] Gloucestershire Royal Hosp NHS Trust, Gloucester, England
[9] Plymouth Univ, Peninsula Sch Med & Dent, Plymouth, England
[10] St Georges Univ Hosp NHS Fdn Trust, London, England
[11] Great Ormond St Hosp Sick Children, Dept Neurol, London, England
[12] Guys & St Thomas Nat Hlth Serv Fdn Trust, London, England
[13] UCL, UCL Queen Sq Inst Neurol, Fac Brain Sci, Queen Sq MS Ctr, London, England
[14] Queen Mary Univ London, Wolfson Inst Populat Hlth, Prevent Neurol Unit, London, England
[15] John Radcliffe Hosp, Childrens Hosp, Dept Paediat Neurol, Oxford, England
关键词
NMOSD; MOGAD; Epidemiology; Bias; NEUROMYELITIS-OPTICA; DISEASE;
D O I
10.1016/j.msard.2024.105553
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare disorders often seen in highly specialized services or tertiary centres. We aimed to assess if cohort characteristics depend on the origin of the referral catchment areas serviced by our centre (i.e. local, regional or national). Methods: Retrospective cohort study using a national referral service database including local (Oxfordshire), regional (Oxfordshire and neighbouring counties), and national patients. We included patients with the diagnosis of NMOSD, seronegative NMOSD or MOGAD, followed at the Oxford Neuromyelitis Optica Service. Results: We included 720 patients (331 with MOGAD, 333 with aquaporin-4 antibody (AQP4)-NMOSD, and 56 with seronegative NMOSD. The distribution of diagnoses was similar across referral cohorts. There were no significant differences in the proportion of pediatric onset patients, sex, or onset phenotype; more White AQP4NMOSD patients were present in the local than in the national cohort (81 % vs 52 %). Despite no differences in follow-up time, more relapsing MOGAD disease was present in the national than in the local cohort (42.9 % vs. 24 %, p = 0.029). Conclusion: This is the first study assessing the impact of potential referral bias in cohorts of NMOSD or MOGAD. The racial difference in the AQP4-NMOSD cohorts likely reflects the variation in the population demographics rather than a referral bias. The over representation of relapsing MOGAD patients in the national cohort probably is a true referral bias and highlights the need to analyze incident cohorts when describing disease course and prognosis. It seems reasonable therefore to compare MOGAD and NMOSD patients seen withing specialised centres to general neurology services, provided both use similar antibody assays.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore
    Foo, Reuben
    Yau, Christine
    Singhal, Shweta
    Tow, Sharon
    Loo, Jing-Liang
    Tan, Kevin
    Milea, Dan
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2022, 11 (02): : 184 - 195
  • [42] Goals and Design of a Dedicated Tertiary Care Centre NMOSD/MOGAD Clinic
    Burton, Jodie
    Alikhani, Katayoun
    Brust, Tyson
    Costello, Fiona
    Harris, Colleen
    Morrow, Sarah
    NEUROLOGY, 2024, 103 (07) : S3 - S4
  • [43] The neuro-ophthalmological manifestations of NMOSD and MOGAD-a comprehensive review
    Moheb, Negar
    Chen, John J. J.
    EYE, 2023, 37 (12) : 2391 - 2398
  • [44] Quantitative MRI measures of MOGAD compared to MS, NMOSD and healthy controls
    Kunchok, A.
    Ontaneda, D.
    Abbatemarco, J.
    Cohen, J. A.
    Nakamura, K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 424 - 425
  • [45] Targeting B cells to modify MS, NMOSD, and MOGAD Part 2
    Graf, Jonas
    Mares, Jan
    Barnett, Michael
    Aktas, Orhan
    Albrecht, Philipp
    Zamvil, Scott S.
    Hartung, Hans-Peter
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (01):
  • [46] Differential mri biomarkers between mogad, aqp4-nmosd and rrms: a magnims multicenter study
    Cortese, R.
    Battaglini, M.
    Prados, F.
    Bianchi, A.
    Haider, L.
    Kappos, L.
    Yaldizli, Oe.
    Mueller, J.
    Lukas, C.
    Bellenberg, B.
    Schneider, R.
    Groppa, S.
    Grothe, M.
    Liu, Y.
    Duan, Y.
    Llufriu, S.
    Sepulveda, M.
    Arrambide, G.
    Sastre-Garriga, J.
    Rovira, A.
    Paul, F.
    Wuerfel, J.
    Jacob, A.
    Barkhof, F.
    De Stefano, N.
    Ciccarelli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 455 - 456
  • [47] Coping Strategies of NMOSD and MOGAD Affected Persons with a Sociological and Psychological Focus (CoMMOnsense)
    Walz, Anna
    Tkachenko, Daria
    Kretschmer, Julian Reza
    Huemmert, Martin W.
    Zimmermann, Tanja
    Trebst, Corinna
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 411 - 412
  • [48] Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives
    Lorefice, L.
    Cortese, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 85
  • [49] New Insights Into the Use of High Dose of Steroids and Plasmaphersis in MOGAD and NMOSD Patients
    Kosior, N.
    Perrier, R. L.
    Casserly, C.
    Morrow, S. A.
    Racosta, J. M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 170 - 171
  • [50] New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD
    Kosior, N.
    Perrier, R. L.
    Casserly, C.
    Morrow, S. A.
    Racosta, J. M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 92